| 摘要 |
A pharmaceutical formulation, comprising: (a) a compound of formula 1 wherein: R<SUP>1 </SUP>is hydrogen, C<SUB>1-4</SUB>-alkyl, -O-C<SUB>1-4</SUB>-alkyl, or halogen; R<SUP>2 </SUP>is hydrogen, C<SUB>1-4</SUB>-alkyl, -O-C<SUB>1-4</SUB>-alkyl, or halogen; R<SUP>3 </SUP>is hydrogen, C<SUB>1-4</SUB>-alkyl, -O-C<SUB>1-4</SUB>-alkyl, halogen, OH, -O-C<SUB>1-4</SUB>-alkylene-COOH, or -O- C<SUB>1-4</SUB>-alkylene-COO-C<SUB>1-4</SUB>-alkyl; and X<SUP>- </SUP>denotes an anion with a single negative charge, or a tautomer, enantiomer, solvate, or hydrate thereof; (b) a second active substance 2 selected from tiotropium salts, oxitropium salts, flutropium salts, ipratropium salts, glycopyrronium salts, and trospium salts, or a tautomer, enantiomer, solvate, or hydrate thereof; (c) at least one pharmacologically acceptable acid; and (d) a solvent selected from water, ethanol, or a mixture of water and ethanol.
|
